Beta Blocker Selectivity Chart: Receptor Ratios, Cardioselectivity, and Clinical Trade-Offs

Beta blocker selectivity is the property that makes a drug bind beta-1 receptors in the heart more tightly than beta-2 receptors in the lungs and blood vessels, and a selectivity chart ranks drugs by that ratio rather than by potency. Most clinical charts list drugs as simply cardioselective or nonselective, but the underlying beta-1 to beta-2 binding ratios vary enormously: metoprolol sits at roughly 15-fold to 75-fold beta-1 preference, bisoprolol reaches about 100-fold to 150-fold in functional assays, while propranolol is essentially nonselective at 1:1 to 2:1. Cardioselectivity is dose-dependent, partial, and lost at high doses, which is why the chart is the starting point for decisions, not the endpoint.

The Receptor Biology Behind Every Selectivity Ratio

Beta-adrenergic receptors are G-protein-coupled receptors that split into three subtypes with distinct jobs. Beta-1 receptors dominate the heart and kidney, where they drive heart rate, contractility, and renin release. Beta-2 receptors sit on bronchial smooth muscle, peripheral vasculature, and skeletal muscle, where activation causes bronchodilation and vasodilation. Beta-3 receptors handle lipolysis and bladder relaxation and matter little in routine prescribing.

Selectivity is a ratio of equilibrium dissociation constants, or of the functional concentrations needed to occupy and block each receptor subtype. A drug with a Ki of 1 nM at beta-1 and 100 nM at beta-2 has a 100-fold beta-1 preference. That ratio is measured in isolated membrane preparations or intact tissue, and the two methods give different numbers.

Selectivity is also not a binary. At a low dose, metoprolol blocks cardiac beta-1 receptors while leaving bronchial beta-2 receptors largely available; titrate upward and beta-2 occupancy climbs until it approaches the nonselective range. In plain terms: every cardioselective beta blocker becomes less selective the more you give.

The clinical payoff of selectivity is fewer beta-2 side effects: less bronchospasm in asthma, less peripheral vasoconstriction, and less interference with hypoglycemia awareness. The cost is that selectivity is a spectrum, not a switch.

The Beta Blocker Selectivity Chart Itself

The table below compiles approximate beta-1 to beta-2 selectivity ratios from receptor binding and functional assay literature. These are orders of magnitude, not precise constants; assay method, species, and tissue shift the numbers by two- to threefold, and no consensus rank order exists across sources.

Two numbers deserve special handling. Carvedilol and labetalol are not truly cardioselective; their vasodilation comes from alpha-1 blockade, not beta-2 sparing. Nebivolol's high beta-1 preference is coupled to nitric oxide-mediated vasodilation, a mechanistically distinct property that the ratio alone does not capture. Nebivolol is also not indicated for heart failure in the United States, which limits its practical use despite the attractive ratio.

Where the Chart Meets the Guidelines

The 2022 AHA/ACC/HFSA heart failure guideline names three beta blockers as class 1 therapy with mortality benefit: carvedilol, metoprolol succinate, and bisoprolol. All three have large randomized trial support, but only two of them are cardioselective on the chart. Carvedilol, the least selective of the trio, carries the most alpha-1 activity and the strongest evidence base in reduced ejection fraction.

Post-myocardial-infarction prescribing leans the other way. The 2017 ACC/AHA hypertension guideline and the chronic coronary disease guideline place cardioselective agents such as metoprolol and atenolol among preferred options, partly to limit bronchospasm and peripheral symptoms during long-term use.

The tension is real and worth naming explicitly. In a patient with both heart failure and reactive airway disease, the chart favors bisoprolol, but the heart failure trial evidence for bisoprolol came from the CIBIS-II trial (1999), and that population excluded severe asthma. Guideline endorsement does not override the clinical reality that cardioselectivity is a probabilistic hedge, not a guarantee.

Atenolol illustrates the gap between chart and outcome. It is moderately cardioselective and widely used, yet it is not recommended for heart failure and has weak outcomes data in uncomplicated hypertension. Selectivity alone does not predict benefit.

Why Selectivity Fails: Mechanisms the Chart Omits

Several mechanisms erode the selectivity a chart promises.

Dose saturation. Beta-2 blockade emerges as the dose rises, because the receptor reserve in the heart is large enough that beta-1 is fully occupied at low doses. Metoprolol at 25 mg twice daily is clearly cardioselective; at 200 mg the margin narrows substantially. There is no clean dose at which any cardioselective drug preserves the full beta-1:beta-2 gap.

Polymorphic metabolism. Metoprolol clearance runs through CYP2D6, and poor metabolizers experience several-fold higher exposure. A CYP2D6 poor metabolizer on 100 mg may carry the beta-2 occupancy of a 300 mg dose. Carvedilol shares this pathway, which is why the 3.125 mg to 25 mg titration is slow. The chart shows a nominal ratio; the patient shows a real one.

Genotype also matters at the target. The ADRB1 Gly389Arg polymorphism changes beta-1 receptor coupling, and observational work suggests carriers respond differently to metoprolol in blood pressure and heart rate endpoints. This is established as a mechanism but not as a dosing rule; no guidelines currently recommend genotype-guided beta blocker selection.

Asthma versus COPD. In asthma, any beta-2 blockade is hazardous because bronchial tone depends on beta-2 signaling. Cardioselective drugs are relatively safer but not safe. In COPD, the risk is lower because the airflow limitation is mostly fixed, and a 2021 review and large observational data support cautious use of cardioselective agents for COPD patients with cardiac indications. The distinction between the two diseases matters more than the chart row.

Hypoglycemia masking. Nonselective agents blunt the beta-2-mediated tremor and palpitations of hypoglycemia and delay glycogenolysis. Cardioselective agents do this less, but the protection is relative. In insulin-treated diabetes, the mechanism favors a cardioselective agent when a beta blocker is genuinely needed, per the 2017 ACC/AHA hypertension guideline.

At-A-Glance Comparison: What Each Property Buys You

The trade-offs are clearer when the chart is read across rows rather than down one column.

Read the heart failure row and the asthma row together and the problem resolves. Carvedilol wins the heart failure row and loses the asthma row. Bisoprolol wins the asthma row and retains a heart failure indication. No beta blocker wins both, which is exactly why the chart cannot be replaced by a single "best" recommendation.

Red Flags and Cautions

Cardioselectivity should never be treated as permission to use a beta blocker without caution in the following settings:

• Severe asthma or a history of beta-agonist-dependent bronchospasm: avoid all beta blockers unless the cardiac indication is compelling and a specialist agrees.
• Decompensated heart failure: start only after euvolemia is achieved, at low doses, with slow titration.
• Significant bradycardia or high-grade atrioventricular block without a pacemaker: cessation or avoidance.
• Cocaine-associated chest pain: nonselective agents can worsen coronary vasoconstriction through unopposed alpha stimulation.
• Concurrent verapamil or diltiazem: additive atrioventricular nodal suppression and negative inotropy.
• Poor CYP2D6 metabolizer status with metoprolol or carvedilol: expect higher exposure and slower titration.

What to Actually Do With the Chart

Use the chart as a starting filter and a decision scaffold, not an answer book.

First, identify whether the patient has any beta-2-sensitive condition, especially asthma. If yes, the chart argues for bisoprolol or nebivolol at the lowest effective dose, with pulmonary monitoring.

Second, match the indication to the trial evidence. Reduced ejection fraction heart failure favors carvedilol, metoprolol succinate, or bisoprolol by class 1 recommendation; do not substitute atenolol or propranolol merely because they appear on the chart.

Third, check the elimination route. Atenolol and nadolol clear renally, so dose-reduce in chronic kidney disease. Metoprolol and carvedilol clear hepatically via CYP2D6, so watch for drug interactions with fluoxetine, paroxetine, and bupropion.

Fourth, titrate to heart rate or blood pressure targets rather than to a fixed dose, and reassess selectivity at each step because dose changes the ratio. A resting heart rate of 55 to 60 beats per minute is a reasonable guide in most stable patients.

Fifth, in diabetes, prefer a cardioselective agent and counsel on hypoglycemia symptoms, because masking is reduced but not eliminated. In COPD, proceed with a cardioselective agent when indicated and monitor symptoms rather than withholding therapy.

Timeline: How Beta Blocker Selectivity Unfolded

The distinction emerged gradually and changed practice each step of the way.

The timeline carries a lesson that is easy to miss. Selectivity drove drug design, but trial outcomes drove guideline adoption, and the two did not always align. Carvedilol's alpha-1 activity and strong evidence base earned it a top spot despite a modest selectivity ratio.

Limitations of Every Selectivity Chart

First, receptor ratios are assay-dependent. Binding studies with cloned human receptors, functional assays in isolated atria, and in vivo hemodynamic measurements produce different rank orders. No single number is definitive.

Second, the ratios are approximate. Published beta-1:beta-2 values for metoprolol range from about 15 to about 75 depending on method and species, so any chart presenting a precise figure should be read as illustrative.

Third, selectivity is dose-dependent and patient-dependent. A chart cannot show a CYP2D6 poor metabolizer's exposure, a patient's receptor genotype, or the local concentration at the bronchial smooth muscle.

Fourth, the clinical endpoints that matter — mortality, hospitalization, exacerbation — are not predicted by receptor ratios alone. They depend on trial populations, dosing strategies, and adherence.

Fifth, most selectivity data come from healthy volunteers or animal tissue, not from the multimorbid patients who actually take these drugs. Extrapolation across that gap is a hypothesis, not an established fact.

In practice, the chart is most useful as a structured way to ask the right questions: Is there beta-2-sensitive disease, what does the trial evidence say for this indication, and how will this patient's metabolism and comorbidities shift the ratio? Answering those three questions does more for the patient than memorizing the rank order of twelve drugs.